Merck & Co., Inc. · MRK · FY2026 Q1 · Calendar Q2 2026

Merck Q1 2026: Revenue Beat and Raised Guidance, But One-Time Charges Weigh on EPS

Merck's Q1 2026 results underscore a company in transition: core Keytruda revenue remains strong, but the earnings profile is being reshaped by large one-time charges (Cidara: $9B) and strategic bets (pending Terns acquisition, Google Cloud AI partnership). Revenue beat consensus by roughly $440M, growing 5% YoY on oncology and animal-health strength. Management raised full-year EPS guidance to $5.04-$5.16, reflecting operational confidence. The pipeline showed breadth with FDA approval of IDVYNSO for HIV, priority reviews for I-DXd and WELIREG combinations, and over 20 planned product launches. However, Gardasil's 22% decline on China and Japan weakness and the approaching Keytruda LOE in 2028-2029 remain meaningful headwinds. The market initially reacted negatively (-2.6% abnormal move) but subsequently drifted +8.7% higher, suggesting investors ultimately looked past the one-time…

Reported Before market openNYSEHealthcare $322.95B market cap
100quality score

Company context

Snapshot as of publication

Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring.…

Earnings scorecard

Reported versus consensus
Reported EPS $-1.28 Consensus $-1
EPS surprise +12.9% Reported versus consensus
Reported revenue $16.29B Consensus $15.85B
Revenue surprise +2.8% Reported versus consensus

Market reaction

prior-close to event-session close
Stock move -1.6% Event window
SPY move +1.0% Same window
Abnormal move -2.6% Stock minus SPY
Volume 1.9× Versus trailing sessions
Subsequent drift +8.7% Up to 20 sessions
MRKSPY benchmark

Follow MRK with an agent that reads every filing, transcript, and price print. Free to start.

Try FN2 free

Transcript intelligence

What changed

Revenue beat consensus by roughly $440M ($16.29B vs. $15.85B est.), up 5% YoY. EPS beat despite the one-time Cidara charge (-$1.28 vs. -$1.47 est.). Full-year EPS guidance raised to $5.04-$5.16 from $5.00-$5.15. New FDA approval of IDVYNSO for HIV. Priority reviews granted for I-DXd (small-cell lung cancer) and WELIREG combinations. Pending Terns Pharmaceuticals acquisition announced with ~$5.8B expected increase in R&D expense. Google Cloud AI partnership launched. Gardasil sales fell 22% on weak China and Japan demand. Keytruda Q3 timing headwind flagged from earlier wholesaler purchasing.

Guidance delta

Full-year EPS guidance raised from $5.00-$5.15 to $5.04-$5.16, with revenue guidance also increased. Guidance sentiment was raised, reflecting operational strength in oncology and animal health despite one-time acquisition charges.

Key takeaways

  • Q1 revenue of $16.3B beat consensus by roughly $440M, up 5% YoY on oncology and animal-health strength
  • EPS guidance raised to $5.04-$5.16 despite a $9B one-time Cidara acquisition charge pushing quarterly EPS to -$1.28 (still ahead of the -$1.47 consensus)
  • FDA approval of IDVYNSO for HIV and priority reviews for I-DXd (small-cell lung cancer) and WELIREG combinations expand near-term commercial opportunity
  • Pending Terns Pharmaceuticals acquisition and Google Cloud AI partnership signal investment in pipeline depth and operational efficiency
  • Gardasil sales fell 22% on weaker demand in China and Japan, a persistent headwind
  • Stock initially dropped 2.6% on the print but subsequently drifted 8.7% higher, suggesting investors looked past one-time charges to the raised outlook

Management priorities

  • Deliver multiple Phase III data readouts over the next 18 months across oncology, cardiometabolic, and ophthalmology
  • Complete the Terns Pharmaceuticals acquisition and integrate TERN-701 for chronic myeloid leukemia
  • Roll out AI capabilities company-wide through the Google Cloud partnership
  • Launch and commercialize over 20 new products across therapeutic areas
  • Implement the new product-focused commercial business-unit model

Related earnings events

Healthcare
UNH · FY2026 Q2 · Calendar Q3 2026UNH Q2 2026: EPS Beat, Guidance Raised as AI and Cost Trends ImproveJNJ · FY2026 Q2 · Calendar Q3 2026JNJ Q2 2026: $25.3B Sales, Guidance Raised to $101.1B Midpoint, New Launches Drive Growth

Sources

  1. Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
  2. FN2 earnings calendar · 2026-07-26T00:37:12.209961+00:00
  3. Polygon adjusted daily market bars · 2026-07-28T09:51:20.553753+00:00
  4. Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-07-28T09:51:20.550881+00:00

Methodology

Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.

Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.

By FN2 Research · Updated . For educational purposes only; not investment advice.